SCHEDULE 13G/A: Investment Funds Disclose 2.0% Stake in Lucid Diagnostics Inc.
Beneficial Ownership Report
Ayrton Capital LLC, Alto Opportunity Master Fund, SPC, and Waqas Khatri have jointly disclosed a 2.0% beneficial ownership stake in Lucid Diagnostics Inc. as of December 31, 2024.
Summary
- A Schedule 13G/A filing indicates that Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri (collectively, the 'Reporting Persons') beneficially own 1,200,485 shares of Lucid Diagnostics Inc. common stock.
- This ownership represents 2.0% of the Issuer's outstanding common stock, based on 59,342,479 shares outstanding as of November 8, 2024, as reported in the Issuer's Form 10-Q.
- The shares are held by Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, a Cayman Islands exempted company, for which Ayrton Capital LLC, a Delaware limited liability company, serves as the investment manager.
- Waqas Khatri serves as the managing member of Ayrton Capital LLC and a director of Alto Opportunity Master Fund, SPC Segregated Master Portfolio B.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Lucid Diagnostics Inc.
Sentiment
Score: 5
Explanation: The document is a routine beneficial ownership disclosure (Schedule 13G/A) and does not contain information that would typically indicate positive or negative sentiment regarding the company's performance or outlook. It is a factual report of an investment stake.
Positives
- The disclosure of a beneficial ownership stake by investment entities like Alto Opportunity Master Fund and Ayrton Capital LLC may signal continued investor interest in Lucid Diagnostics Inc.
Negatives
- The document does not contain information that would typically be categorized as negatives regarding the issuer's performance or outlook, as it is a beneficial ownership report.
Risks
- This filing, a Schedule 13G, primarily reports beneficial ownership and does not detail specific risks related to Lucid Diagnostics Inc.'s operations or financial health.
Future Outlook
This Schedule 13G/A filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Lucid Diagnostics Inc.'s future outlook.
Industry Context
This document is a routine beneficial ownership filing and does not provide specific insights into broader industry trends or competitive landscape for Lucid Diagnostics Inc.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant ownership stakes by institutional investors, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 2024-11-08 | Date as of which 59,342,479 shares of Common Stock were outstanding, as reported in the Issuer's Form 10-Q. |
| 2024-11-12 | Date the Issuer's Form 10-Q was filed, which provided the shares outstanding figure. |
| 2024-12-31 | Date of event which requires filing of this statement (reporting date for beneficial ownership). |
| 2025-02-13 | Date the Schedule 13G/A filing was signed. |
Keywords
Lucid Diagnostics Inc., Common Stock, Schedule 13G, Beneficial Ownership, Ayrton Capital LLC, Alto Opportunity Master Fund, Waqas Khatri, Investment Management, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.